IGM Biosciences Inc (NAS:IGMS)
$ 11.47 3.06 (36.39%) Market Cap: 677.00 Mil Enterprise Value: 243.55 Mil PE Ratio: 0 PB Ratio: 4.19 GF Score: 33/100

IGM Biosciences Inc Review of IGM-2323 Data Presented at the 62nd Annual ASH Meeting - Conference Call Transcript

Dec 05, 2020 / 07:00PM GMT
Operator

Good day, everyone, and welcome to the IGM Biosciences conference call and webcast to review the IGM-2323 data presented today at the 62nd Annual ASH meeting. Today's call is being recorded. (Operator Instructions)

At this time, I would now like to turn the call over to Fred Schwarzer, Chief Executive Officer.

Fred M. Schwarzer
IGM Biosciences, Inc. - CEO, President & Director

Thank you, operator, and welcome to all of you joining us today. I would like to thank you for taking time on your Saturday to join this presentation. All of us at IGM have been eagerly awaiting this day for 15 months ever since we dosed our first patient last year, and we are very excited and pleased to share our excellent initial efficacy and safety data from the clinical trial of IGM-2323.

This presentation contains certain forward-looking statements. And we must advise you that these forward-looking statements are subject to many factors which are beyond our control, and they should not be relied upon as predictions of future events. In this regard, we direct

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot